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Genetics
Polymorphisms in ARMS2/HTRA1 and Complement Genes
and Age-Related Macular Degeneration in India: Findings
from the INDEYE Study
Periasamy Sundaresan,1 Praveen Vashist,2 Ravilla D. Ravindran,3 Ashwini Shanker,1
Dorothea Nitsch,4 Bareng A. S. Nonyane,4 Liam Smeeth,4 Usha Chakravarthy,5 and
Astrid E. Fletcher4
PURPOSE. Association between genetic variants in complement
factor H (CFH), factor B (CFB), component 2 (C2), and in the
ARMS2/HTRA1 region with age-related macular degeneration
(AMD) comes mainly from studies of European ancestry and
case-control studies of late-stage disease. We investigated
associations of both early and late AMD with these variants
in a population-based study of people aged 60 years and older
in India.
METHODS. Fundus images were graded using the Wisconsin Age-
Related Maculopathy Grading System and participants assigned
to one of four mutually exclusive stages based on the worse
affected eye (0 ¼ no AMD, 1–3 ¼ early AMD, 4 ¼ late AMD).
Multinomial logistic regression was used to derive risk ratios
(RR) accounting for sampling method and adjusting for age,
sex, and study center.
RESULTS. Of 3569 participants, 53.2% had no signs of AMD,
45.6% had features of early AMD, and 1.2% had late AMD. CFH
(rs1061170), C2 (rs547154), or CFB (rs438999) was not
associated with early or late AMD. In the ARMS2 locus,
rs10490924 was associated with both early (adjusted RR 1.22,
95% confidence interval [CI]: 1.13–1.33, P < 0.0001) and late
AMD (adjusted RR 1.81, 95% CI: 1.15–2.86; P ¼ 0.01);
rs2672598 was associated only with early AMD (adjusted RR
1.12, 95% CI: 1.02–1.23; P ¼ 0.02); rs10490923 was not
associated with early or late AMD.
CONCLUSIONS. Two variants in ARMS2/HTRA1 were associated
with increased risk of early AMD, and for one of these, the
increased risk was also evident for late AMD. The study
provides new insights into the role of these variants in early
stages of AMD in India. (Invest Ophthalmol Vis Sci. 2012;
53:7492–7497) DOI:10.1167/iovs.12-10073
The late stage of age-related macular degeneration (AMD) isthe major cause of serious vision loss in Western
populations. Over the past decade, strong genetic associations
have been identified in persons with types of late AMD
(neovascular AMD and/or geographic atrophy).1,2 These
studies have been largely undertaken in Western settings,3–16
with few located in countries such as India where there is a
burgeoning growth in the older age groups.17–20 Furthermore,
few studies have explored genetic associations with early AMD
features and thus the role of the former in the pathogenesis of
the condition remains poorly researched.21–24
We investigated genetic associations with both early and
late AMD using a large population-based study in north and
south India: the India Age-related Eye disease Study
(INDEYE). We examined variants in a range of genes that
have been previously identified primarily in Western
studies.2,8,13–17,19,20,25
METHODS
Study Participants and Procedures
We used data already collected from a population-based study of
people aged 60 years and older: the INDEYE study. The objectives of
the INDEYE study were to estimate the prevalence of early and late
AMD and of lens opacities, as well as to investigate associations of
these conditions with lifestyle factors. The study design, procedures,
and results of AMD prevalence in INDEYE have been reported
elsewhere.26 The study took place in two locations: in Haryana state,
north India, and Tamil Nadu, south India. Sampled clusters were
enumerated to identify people aged 60 and older who were invited to
participate in the study. Recruitment into the study was performed
between 2005 and 2007. Informed written consent was obtained from
all participants before enrollment. Information was read to people who
were illiterate in the presence of a local witness, and a thumb
impression of the participant signified assent. The study complied with
the guidelines in the Declaration of Helsinki, and ethics approval was
received from the Research Ethics Committees of the All India Institute
of Medical Sciences, Aravind Eye Hospital, London School of Hygiene
and Tropical Medicine, Queens University Belfast, and the Indian
Council for Medical Research.
Information on household characteristics and sociodemographic
variables was collected at enumeration for INDEYE. A structured
questionnaire was used to collect data about lifestyle, including
tobacco and alcohol use and participants came to the base hospital for
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a clinical examination, which included anthropometry, blood pressure,
an eye examination, and blood sample collection. Of the 3874
households from which participants were eligible, there were 2898
(74.8%) with a single participant, 948 (24.5%) households with two
participants each, 25 (0.6%) households with three participants each,
and three (0.1%) households with four participants each. In most
households (87.6%) with two or more participants, there was no
biological relation between the participants. Only 4.0% of households
had related participants and in 8.4% of the households the biological
relationships were uncertain.
Grading of AMD
Full details of the fundus grading and prevalence have been provided
elsewhere.26 Two 358 stereo fundus images (TRC 50 EX; Topcon
Corporation, Tokyo, Japan) were obtained from each eye and graded
using the Wisconsin Age-Related Maculopathy Grading System
(WARMGS)27 at a single reading center (Department of Ophthalmology
and Vision Science, Queens University Belfast). Features of AMD were
classified into one of five mutually exclusive severity stages of the
Rotterdam staging system: stage 1, soft distinct drusen (‡63 lm) only
or pigmentary irregularities only; stage 2, soft indistinct (‡125 lm) or
reticular drusen only or soft distinct drusen (‡63 lm) with pigmentary
irregularities; stage 3, soft indistinct (‡125 lm) or reticular drusen
with pigmentary irregularities; stage 4, either choroidal neovascular-
ization (CNV; presence of any of the following: serous or hemorrhagic
retinal or retinal pigment epithelial detachment, subretinal neovascular
membrane, and periretinal fibrous scar) or geographic atrophy (GA;
well-demarcated area of retinal pigment atrophy with visible choroidal
vessels).
Genotyping
We chose single-nucleotide polymorphisms (SNPs) that were previ-
ously published showing associations for late AMD in India and Europe.
For complement factor H (CFH), we chose rs1061170 and for
component 2 (C2) we chose rs547154, as this had been the most
significant signal for late AMD in a previous Indian case-control study.17
A previous European study had characterized a potentially non-
synonymous coding variant R151Q near complement factor B (CFB)
in the SKIV2L gene (rs438999).28 In the HtrA serine peptidase 1
(HTRA1)/age-related macular susceptibility 2 (ARMS2) region, we
selected rs10490923, rs10490924, and rs2672598, as these SNPs
captured common haplotypes in this region previously associated with
late AMD in an Indian case-control study.19
Genomic DNA was extracted from peripheral blood leukocytes
using Quiagen kits (Qiagen GmbH, Hilden, Germany). DNA concen-
tration was standardized for working DNA using an Eppendorff
automatic pipetting machine (Eppendorf AG, Hamburg, Germany).
DNA was plated into 384 wells, and the three SNPs were genotyped
using TaqMan assays in an ABI 7900 real-time PCR (Applied Biosystems,
Foster City, CA). The genotyping procedure was performed according
to the manufacturer’s protocol. Clustering of genotypes was inspected
for separation between genotypes and accuracy of genotype calls.
Clustering algorithms for genotype assignment used three quality-
control steps: (1) all individual calls with a significant number of outlier
SNPs were checked for DNA concentration and plated DNA amended
accordingly, (2) setting an SNP pass value by assigning a pass or fail
status for each SNP and genotyping plate, and (3) genotyping was
repeated for calls that did not pass in the first run (5% of calls). All steps
for sample preparation and genotyping were automated and tracked
with a bar-coding system that fed data directly into a database, which
then provided genotyping results for individual samples.
Statistical Analysis
All analyses were done in STATA 11 (StataCorp 2007, College Station,
TX). Early AMD was defined as stages 1, 2, and 3 and late AMD as stage
4. People with no sign of early or late AMD were classified as ‘‘no
AMD.’’ The numbers for analysis were as follows: no AMD features (n¼
1899), early AMD (n ¼ 1628), and late AMD (n ¼ 42). Power
calculations showed that for variants with minor allele frequencies
(MAFs) of 0.1, 0.2, and 0.3, the study had 77%, 96%, and 99% power,
respectively, to detect allelic associations of 1.2 and larger with early
AMD at P ¼ 0.05.
Multinomial logistic regression was used to investigate associations
with early or late AMD with people with no AMD as the baseline
comparison group. Multinomial logistic regression was expressed as
relative risk ratios (RRR). All analyses used robust SEs to take account
of the cluster-sampling design.
We undertook unadjusted associations between AMD and SNP
genotypes, then we adjusted for age, sex, and study location. Age was
included as a continuous variable. We fitted models that allowed for
separate effects of the heterozygous genotypes and risk/rare homozy-
gous genotypes, as well as those that allowed for additive genotype
effects.
Sensitivity Analyses
In sensitivity analyses, caste and socioeconomic status (based on
housing characteristics) were investigated for confounding effects
because these could potentially lead to nonrandom mating in the
population, whereas tobacco use, diabetes status, and body mass index
were included to investigate if they improved the precision of the
association. Results did not change on further adjustment (data not
shown), and therefore the age-, sex-, and study location–adjusted
analyses are shown in the main text.
Most (87%) of the households with multiple participants (consti-
tuting 25% of all households) had no biological relations and the
analysis using robust SEs allowed for clustering in households and
villages. Sensitivity analyses were carried out excluding all participants
with possible relations in the same household (see Supplementary
Material, http://www.iovs.org/lookup/suppl/doi:10.1167/iovs.
12-10073/-/DCSupplemental).
Exclusion of the nine AMD stage 3 cases did not change results
(data not shown).
Because tobacco smoking in particular has been found to have
modifying effects for ARMS2/HTRA1 rs10490924 in some studies on
European populations,10,29 we tested for an interaction with tobacco
use (current, ex, never) using design-adjusted Wald-tests (allowing for
the clustered sampling design). In view of different genotype
frequencies by location for rs1061170 and rs10490924, we investigat-
ed in sensitivity analyses whether results differed by study location.
RESULTS
Full details of distribution of the AMD severity stages in the
INDEYE sample have been previously reported.26 The demo-
graphic characteristics of participants with a blood sample and
at least one genotype are shown in Table 1. In our population,
the use of any type of tobacco (current or past) was 61%; 42%
had ever smoked, 13% only chewed tobacco, 6% had both
chewed and smoked tobacco, and 39% had never used
tobacco. Most smokers (83%) smoked beedies (hand-rolled
tobacco) and only 7% smoked imported Western cigarettes.
The Supplementary Table 1 (see Supplementary Material
and Supplementary Table 1, http://www.iovs.org/lookup/
suppl/doi:10.1167/iovs.12-10073/-/DCSupplemental) shows
the SNP genotype distributions by AMD stages and associated
genes. Hardy-Weinberg equilibrium was maintained for all SNPs
in the control group. We checked our observed genotype
frequencies against published literature and genetic databases.
When investigating genotype frequencies by study location, we
found a slightly higher MAF for Y402H, and a slightly lower
MAF for rs10490924 in north India than in south India (see
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Supplementary Material and Supplementary Table 2, http://
www.iovs.org/lookup/suppl/doi:10.1167/iovs.12-10073/-/
DCSupplemental). Both genotype frequencies of the CFH
Y402H rs1061170 were similar to those previously reported.30
The MAF of rs438999 (near CFB) and rs547154 (complement
C2) were both 0.18, which was more than twice the MAF
observed for central European populations (0.08 and 0.06
respectively) but in accord with previous observations made in
Texas Gujarati Indians (MAF ¼ 0.16 for both SNPs).31,32 The
observed MAF of 0.14 for rs10490923 in our study (ARMS2)
was similar to central Europeans (MAF¼ 0.13),33 but MAFs for
rs10490924 (ARMS2) and rs2672598 (HTRA1) were higher
(0.32 and 0.53) when compared with 0.27 and 0.43 in
Europeans, respectively.34,35 The MAF of 0.32 for rs10490924
in our study was similar to that observed in Gujarati Indians
(MAF ¼ 0.36)34 and to that reported by Kaur et al.19 in a
population from southern India. There was no published
population-based MAF for Indians for rs2672598.
Preliminary analysis showed that the associations between
stage 1 and stage 2 AMD with the variants was similar (there
were too few cases of stage 3 for separate analysis) and we
therefore merged the three early-AMD stages into a single
group because of the small numbers in stages 2 (n¼240) and 3
(n¼ 9) relative to stage 1 (n¼ 1379). Table 2 shows crude and
adjusted associations for complement pathway SNPs that have
been associated with AMD in European studies,8,14–16 and with
late AMD in an Indian case-control study.17,20 There was no
evidence for an association between rs1061170 and early
stages of AMD irrespective of type of genetic model. Analyses
found no evidence of effect modification by study location (P
value for interaction ¼ 0.138). For late-stage AMD, the point
estimates suggest a per-allele increase in risk of 1.50, 95%
confidence interval (CI) 0.96 to 2.34 in the age-, sex-, and
location-adjusted analyses, P ¼ 0.08. For the SNPs in C2
(rs547154) and CFB (rs438999), there was no evidence of
association with early or late AMD.
Table 3 shows association results for SNPs in the HTRA/
ARMS2 region. There was no evidence of association for
rs10490923 (ARMS2) with early or late AMD. For rs10490924
(ARMS2) and rs2672598 (HTRA1), associations were observed
with early stages of AMD. Only rs10490924 was associated
with late AMD. In an adjusted allelic analysis of rs10490924
(ARMS2), having one T allele or more increased the relative risk
of early AMD by 22% (RRR 1.22, 95% CI: 1.13–1.33), and the
relative risk of late AMD by 80% (RRR 1.81, 95% CI: 1.15–2.86).
Analyses found no evidence of effect modification by study
location (P value for interaction ¼ 0.916). For rs2672598
(HTRA1), having one G allele or more increased the risk of
TABLE 1. Characteristics of Participants by AMD Stage for Those Who
Have at Least One of the Genotyped SNPs
Persons No AMD* Early AMD* Late AMD*
3569 1899 1628 42
Study center
South India 1734 874 (46.0) 837 (51.4) 23 (54.8)
North India 1835 1025 (54.0) 791 (48.6) 19 (45.2)
Age category
60 to 69 2528 1369 (72.1) 1140 (70.0) 19 (45.2)
‡70 1041 530 (27.9) 488 (30.0) 23 (54.8)
Sex
Male 1753 897 (47.2) 835 (51.3) 21 (50.0)
Female 1816 1002 (52.8) 793 (48.7) 21 (50.0)
* Column percentages.
TABLE 2. Crude and Adjusted RRRs with their 95% CIs and P Values for the Associations between AMD and SNPs within or near Genes Involved in
the Complement Pathway
CT versus TT CC versus TT Additive Model
CFH
rs1061170
Early AMD RRR (95% CI) P value
Unadjusted 0.88 (0.76–1.01) P ¼ 0.07 0.93 (0.73–1.18) P ¼ 0.53 0.93 (0.84–1.03) P ¼ 0.17
Age, sex, and location adjusted 0.88 (0.77–1.02) P ¼ 0.09 0.93 (0.73–1.18) P ¼ 0.5 0.94 (0.84–1.04) P ¼ 0.20
Late AMD RRR (95% CI) P value
Unadjusted 1.75 (0.84–3.66) P ¼ 0.14 2.15 (0.75–6.16) P ¼ 0.15 1.50 (0.97–2.34) P ¼ 0.07
Age, sex, and location adjusted 1.70 (0.81–3.58) P ¼ 0.16 2.15 (0.76–6.07) P ¼ 0.15 1.50 (0.96–2.34) P ¼ 0.08
AC versus CC AA versus CC Additive Model
Complement C2
rs547154
Early AMD RRR (95% CI) P value
Unadjusted 0.93 (0.79–1.10) P ¼ 0.41 1.30 (0.94–1.79) P ¼ 0.12 1.00 (0.89–1.12) P ¼ 0.96
Age, sex, and location adjusted 0.93 (0.79–1.10) P ¼ 0.42 1.27 (0.92–1.76) P ¼ 0.14 1.00 (0.89–1.12) P ¼ 0.99
Late AMD RRR (95% CI) P value
Unadjusted 1.12 (0.60–2.09) P ¼ 0.72 1.82 (0.44–7.61) P ¼ 0.41 1.21 (0.69–2.11) P ¼ 0.51
Age, sex, and location adjusted 1.13 (0.60–2.10) P ¼ 0.41 1.87 (0.44–7.97) P ¼ 0.40 1.22 (0.69–2.16) P ¼ 0.51
AG versus AA GG versus AA Additive Model
Near CFB, in exon of SKIV2L (DEAD box protein, putative RNA helicase involved in antiviral activity)
rs438999
Early AMD stage 2 RRR (95% CI) P value
Unadjusted 0.94 (0.80–1.11) P ¼ 0.48 1.24 (0.88–1.75) P ¼ 0.23 1.00 (0.89–1.12) P ¼ 0.99
Age, sex, and location adjusted 0.94 (0.80–1.11) P ¼ 0.49 1.23 (0.87–1.73) P ¼ 0.24 1.00 (0.89–1.12) P ¼ 0.99
Late AMD RRR (95% CI) P value
Unadjusted 1.13 (0.59–2.14) P ¼ 0.72 0.91 (0.12–6.85) P ¼ 0.92 1.07 (0.60–1.90) P ¼ 0.83
Age, sex, and location adjusted 1.14 (0.59–2.18) P ¼ 0.70 0.93 (0.12–7.16) P ¼ 0.95 1.08 (0.60–1.95) P ¼ 0.80
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early AMD by 12% (adjusted allelic RRR 1.12, 95% CI: 1.02–
1.23), but there was no evidence of an association with late
AMD for this SNP.
We found no modifying effects of tobacco use with ARMS2/
HTRA1, either for any tobacco use, or specifically for tobacco
smoking or for tobacco chewing. The sensitivity analyses
excluding study participants with multiple relations in the
same household were of similar magnitude and direction (see
Supplementary Material and Supplementary Tables 3, 4, http://
www.iovs.org/lookup/suppl/doi:10.1167/iovs.12-10073/-/
DCSupplemental). The association for rs2672598 (HTRA1) was
not detectable in this subsample with 26% reduced sample
size.
DISCUSSION
For our study of genetic risk factors of early AMD, we restricted
our analysis to well-characterized SNPs that have been
extensively studied in European and Indian case-control studies
of late AMD.13–17,19,20,25,36,37 Variants in CFH, C2, and CFB
shown to be associated with AMD in Western populations did
not appear to increase the risk of early forms of AMD in India.
Two variants in the ARMS2/HTRA1 region were associated
with increased risk of early AMD. The point estimate of the
association of the Y402H SNP in CFH with late AMD was
consistent with previously published European studies.13–16,38
However, the present study had limited power to confirm
previously reported associations with late AMD, which may
explain the lack of association signals with late AMD for all
except one of the candidates studied.
Our study found a high prevalence of early AMD, in
particular stage 1 AMD, which reached nearly 40% prevalence
in both study centers.26 The European EUREYE study used the
same grading system as the INDEYE study and found similarly
that 36.48% (95% CI, 32.66%–40.30%) of the study population
aged 65 or older was graded as early AMD stage 1.39 Thus, the
prevalence of early stage 1 AMD in India is comparable to
Europe. As shown previously,26 the INDEYE study population
had a low frequency of persons with more advanced features
of both early AMD (stages 2 or 3) and late AMD.
Studies in Europe have reported associations between early
A M D a n d C F H Y 4 0 2 H r s 1 0 6 1 1 7 0 a n d A R M S 2
(rs10490924).40–42 Of the candidate SNPs tested, we found
associations only with HTRA1/ARMS2 region and early AMD.
Our study had high power to detect associations with early
AMD. For example, given that the MAF for CFH Y402H was 0.3
in the INDEYE study, there was 99% power to detect an
association of an odds ratio (OR) of 1.2 with early AMD if it was
present. The Munster study in Germany had reported an allelic
OR of 1.9 (99% CI: 1.2–2.9) for the association of CFH Y402H
with stage 1 AMD.41
In an Indian case-control study, Y402H has been shown to
be a risk factor for late AMD with an 11-fold OR reported for
the homozygous C genotype.20 Furthermore, an ecological
study of late AMD suggested that the allele frequencies for
Y402H in India are as expected, given the observed Indian
prevalence of late AMD by age.43 There is to date no other
study of early AMD in India. The absence of an association with
CFH Y402H rs1061170 may suggest alternative molecular
pathways for the development of early AMD features in India
when compared with Europe.
Different polymorphisms in the HTRA region have been
associated with slightly different phenotypes of advanced
AMD: for example, rs1040924 has been associated with earlier
age of onset of AMD, whereas rs2672598 was associated with
differences of retinal pigment epithelium pigmentation.44
These findings would fit with our observations for early
TABLE 3. Crude and Adjusted RRRs with their 95% CIs and P Values for the Associations between AMD and SNPs within or near HTRA1 and ARMS2
AG versus GG AA versus GG Additive Model
ARMS 2
rs10490923
Early AMD RRR (95% CI) P value
Unadjusted 1.00 (0.86–1.16) P ¼ 0.97 1.01 (0.63–1.60) P ¼ 0.98 1.00 (0.87–1.15) P ¼ 0.99
Age, sex, and location adjusted 1.00 (0.87–1.16) P ¼ 0.96 1.02 (0.65–1.62) P ¼ 0.92 1.01 (0.88–1.15) P ¼ 0.93
Late AMD RRR (95% CI) P value
Unadjusted 0.99 (0.45–2.19) P ¼ 0.98 1.03 (0.15–6.88) P ¼ 0.98 1.00 (0.55–1.82) P ¼ 0.99
Age, sex, and location adjusted 0.97 (0.44–2.15) P ¼ 0.94 1.03 (0.17–6.40) P ¼ 0.98 0.98 (0.54–1.81) P ¼ 0.96
GT versus GG TT versus GG Additive Model
rs10490924
Early AMD RRR (95% CI) P value
Unadjusted 1.17 (1.01–1.34) P ¼ 0.03 1.61 (1.32–1.96) P < 0.0001 1.26 (1.13–1.35) P < 0.0001
Age, sex, and location adjusted 1.16 (1.01–1.32) P ¼ 0.04 1.57 (1.29–1.91) P < 0.0001 1.22 (1.13–1.33) P < 0.0001
Late AMD RRR (95% CI) P value
Unadjusted 1.33 (0.63–2.83) P ¼ 0.46 3.44 (1.51–7.85) P ¼ 0.003 1.79 (1.13–2.86) P ¼ 0.02
Age, sex, and location adjusted 1.40 (0.66–2.96) P ¼ 0.38 3.50 (1.53–8.00) P ¼ 0.003 1.81 (1.15–2.86) P ¼ 0.01
AG versus AA GG versus AA Additive Model
HTRA1
rs2672598
Early AMD RRR (95% CI) P value
Unadjusted 1.07 (0.90–1.27) P ¼ 0.45 1.25 (1.03–1.52) P ¼ 0.03 1.12 (1.02–1.24) P ¼ 0.02
Age, sex, and location adjusted 1.06 (0.89–1.25) P ¼ 0.52 1.24 (1.02–1.51) P ¼ 0.03 1.12 (1.02–1.23) P ¼ 0.02
Late AMD RRR (95% CI) P value
Unadjusted 2.42 (0.94–6.23) P ¼ 0.06 2.40 (0.79–7.32) P ¼ 0.12 1.37 (0.90–2.10) P ¼ 0.15
Age, sex, and location adjusted 2.42 (0.97–6.06) P ¼ 0.06 2.51 (0.82–7.63) P ¼ 0.11 1.41 (0.91–2.17) P ¼ 0.12
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AMD. Also, the association found for rs10490924 (ARMS2) in
our study was within the confidence range of the Munster
study of early AMD.41 The previous Indian case-control study of
the HTRA region studied cases with late AMD and found no
association for rs10490923, for rs10490924 an OR of 8.24
(4.54–14.94; comparing TT to GG), and for rs2672598 an OR
of 5.14 (2.86–9.24, comparing GG versus AA).19 These
associations are broadly consistent with our study findings;
as outlined previously we had too few cases of AMD to detect
associations with late AMD. In contrast to previous studies that
described marked effect modification for rs10490924 by
smoking,10 we did not find an interaction between tobacco
use and the risk alleles at the ARMS2 locus. The type of
smoking habit in India varies from Western populations. In
India, men tend to smoke beedies (made from home-grown
tobacco). In southern India, chewing tobacco is more
prevalent than in the north, especially among women, and in
the northern states of India, huqqa smoking is more common
among both sexes. These differences in exposure to tobacco-
derived products may have contributed to the lack of
association for the other ARMS2/HTRA1 variants studied here.
The low use of smoking Western-style cigarettes meant we
were unable to investigate this type of tobacco use.
The strengths of our study were the random sampling used
to identify a representative population sample, the uniform
criteria (WARMGS) used to grade fundus images, and the
availability of robust demographic information. The associa-
tions between ARMS2 and early AMD have not previously been
reported in the Indian population. We found MAFs for our
candidate SNPs that were comparable with published frequen-
cies in reference databases. However, we did note differences
that may be due to random sampling variation or because of
the use of hospital-based controls with their inherent biases in
the study by Kaur et al.17
One limitation of our study was the exclusion of 27% of
study participants who had ungradable fundus images owing to
cataract. However, genotype and allele frequencies in this
group were similar to the group with no signs of AMD (data
not shown). Some of our participants shared the same
households (25% of all households) but there were no
biological relationships in 87.6% of the households that had
multiple participants. Our analysis used robust SEs to allow for
the clustering in households and villages. In sensitivity
analyses, excluding all participants for whom there may be
biological relations in the same household found broadly
similar results. Hence, it is unlikely that there is residual
confounding by consanguinity in our analyses. As this study
was aimed at undertaking confirmatory genetic analyses,
adjustment for multiple testing was not carried out.
In conclusion, we have found associations of SNPs within
the ARMS2 and HTRA1 region with early AMD in India, but
no association of early AMD with CFH Y402H. These findings
suggest that sequence of pathways by which AMD develops
in India may differ from those present in European
populations.
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